

Prof. Dr. Ugur Sahin

*19.09.1965

CEO TRON gGmbH
CEO BioNTech SE
Deputy Head of the University Center for Tumor Diseases (UCT)

University Medical Center of the Johannes Gutenberg University Mainz
D-55131 Mainz, Langenbeckstr. 1
Tel: 06131 2161-201
wheinen@uni-mainz.de



Academia

- 1984 - 1992 Studies in medicine, University of Cologne
- 1992 - 1994 Studies in mathematics, University of Hagen
- 1999 Habilitation in Molecular Medicine and Immunology

Career

- 1991 - 1992 Assistant physician for internal medicine (Köln, Homburg/Saar)
- 1992 - 2000 Assistant physician for internal medicine (Homburg/Saar)
- 2000 Visiting scientist at the Institute for Experimental Immunology (Zurich)
- 2000 Junior group leader of SFB 432 (Mainz)
- 2001 Founding member of Ganymed Pharmaceuticals (Mainz)
- 2003 Chairman of the Tumor Vaccine Center (Mainz)
- 2006 Private lecturer, department for experimental and translational oncology (Mainz)
- 2009 Founding member of BioNTech SE (Mainz)
- 2010 Founding chairman of TRON (Mainz)

Awards

- 1995 Merit Award of the American Society of Oncology
- 1995 Vincenz Czerny Prize of the German Society for Hematology and Onkology
- 1997 Calogero-Paglierello-Research-Award
- 2005 Georges Köhler-Preize of the German Society for Immunology
- 2006 & 2010 GoBio Award of the Federal Ministry of Education and Research (BMBF)
- 2011 STEP Award
- 2012 BMBF Excellence Cluster Award (TRON)
- 2019 German Cancer Award

Selected Publications

Sahin U, Türeci Ö. Personalized vaccines for cancer immunotherapy. *Science*. 2018 Mar 23;359(6382):1355-1360.

Sahin U, Derhovanessian E, Miller M, Kloke BP, Simon P, Löwer M, Bukur V, Tadmor AD, Luxemburger U, Schrörs B, Omokoko T, Vormehr M, Albrecht C, Paruzynski A, Kuhn AN, Buck J, Heesch S, Schreeb KH, Müller F, Ortseifer I, Vogler I, Godehardt E, Attig S, Rae R, Breitkreuz A, Tolliver C, Suchan M, Martic G, Hohberger A, Sorn P, Diekmann J, Ciesla J, Waksman O, Brück AK, Witt M, Zillgen M, Rothermel A, Kasemann B, Langer D, Bolte S, Diken M, Kreiter S, Nemecek R, Gebhardt C, Grabbe S, Höller C, Utikal J, Huber C, Loquai C, Türeci Ö. Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer. *Nature*. 2017 Jul 13;547(7662):222-226.

Kreiter S, Vormehr M, van de Roemer N, Diken M, Löwer M, Diekmann J, Boegel S, Schrörs B, Vascotto F, Castle JC, Tadmor AD, Schoenberger SP, Huber C, Türeci Ö, **Sahin U**. Mutant MHC class II epitopes drive therapeutic immune responses to cancer. *Nature*. 2015 Apr 30;520(7549):692-6.

Stadler CR, Bähr-Mahmud H, Celik L, Hebich B, Roth AS, Roth RP, Karikó K, Türeci Ö, **Sahin U**. Elimination of large tumors in mice by mRNA-encoded bispecific antibodies. *Nat Med*. 2017 Jul;23(7):815-817

Canli Ö, Nicolas AM, Gupta J, Finkelmeier F, Goncharova O, Pesic M, Neumann T, Horst D, Löwer M, **Sahin U**, Greten FR. Myeloid Cell-Derived Reactive Oxygen Species Induce Epithelial Mutagenesis. *Cancer Cell*. 2017 Dec 11;32(6):869-883.e5. doi: 10.1016/j.ccell.2017.11.004.

Pastor F, Berraondo P, Etxeberria I, Frederick J, **Sahin U**, Gilboa E, Melero I. An RNA toolbox for cancer immunotherapy. *Nat Rev Drug Discov*. 2018 Oct;17(10):751-767.

Sahin U, Karikó K, Türeci Ö. mRNA-based therapeutics--developing a new class of drugs. *Nat Rev Drug Discov*. 2014 Oct;13(10):759-80.

Kranz LM, Diken M, Haas H, Kreiter S, Loquai C, Reuter KC, Meng M, Fritz D, Vascotto F, Hefesha H, Grunwitz C, Vormehr M, Hüsemann Y, Selmi A, Kuhn AN, Buck J, Derhovanessian E, Rae R, Attig S, Diekmann J, Jabulowsky RA, Heesch S, Hassel J, Langguth P, Grabbe S, Huber C, Türeci Ö, **Sahin U**. Systemic RNA delivery to dendritic cells exploits antiviral defence for cancer immunotherapy. *Nature*. 2016 Jun 16;534(7607):396-401.

Hinz T, Kallen K, Britten CM, Flamion B, Granzer U, Hoos A, Huber C, Khleif S, Kreiter S, Rammensee HG, **Sahin U**, Singh-Jasuja H, Türeci Ö, Kalinke U. The European Regulatory Environment of RNA-Based Vaccines. *Methods Mol Biol*. 2017;1499:203-222. Review.

Diken M, Kranz LM, Kreiter S, **Sahin U**. mRNA: A Versatile Molecule for Cancer Vaccines. *Curr Issues Mol Biol*. 2017;22:113-128.